157 related articles for article (PubMed ID: 11491013)
1. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.
Teicher BA; Menon K; Alvarez E; Liu P; Shih C; Faul MM
In Vivo; 2001; 15(3):185-93. PubMed ID: 11491013
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul M
Clin Cancer Res; 2001 Mar; 7(3):634-40. PubMed ID: 11297259
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
Cancer Chemother Pharmacol; 2001 Dec; 48(6):473-80. PubMed ID: 11800028
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.
Teicher BA; Alvarez E; Menon K; Esterman MA; Considine E; Shih C; Faul MM
Cancer Chemother Pharmacol; 2002 Jan; 49(1):69-77. PubMed ID: 11855754
[TBL] [Abstract][Full Text] [Related]
7. A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
Sugisawa N; Nishino H; Higuchi T; Park JH; Yamamoto J; Tashiro Y; Kawaguchi K; Bouvet M; Unno M; Hoffman RM
Anticancer Res; 2020 Oct; 40(10):5393-5397. PubMed ID: 32988858
[TBL] [Abstract][Full Text] [Related]
8. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
[TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
10. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
Teicher BA; Forler P; Menon K; Phares V; Amsrud T; Shih C
In Vivo; 2000; 14(4):471-80. PubMed ID: 10945160
[TBL] [Abstract][Full Text] [Related]
11. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
Jia L; Zhang MH; Yuan SZ; Huang WG
World J Gastroenterol; 2005 Jan; 11(3):447-50. PubMed ID: 15637766
[TBL] [Abstract][Full Text] [Related]
13. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
15. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
16. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Wang W; Gallant JN; Katz SI; Dolloff NG; Smith CD; Abdulghani J; Allen JE; Dicker DT; Hong B; Navaraj A; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(3):229-38. PubMed ID: 21725212
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
18. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
Qin Y; Halmos G; Cai RZ; Szoke B; Ertl T; Schally AV
J Cancer Res Clin Oncol; 1994; 120(9):519-28. PubMed ID: 8045917
[TBL] [Abstract][Full Text] [Related]
19. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
